Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH).

Carrieri MP, Serfaty L, Vilotitch A, Winnock M, Poizot-Martin I, Loko MA, Lions C, Lascoux-Combe C, Roux P, Salmon-Ceron D, Spire B, Dabis F; ANRS CO13 HEPAVIH Study Group.

Clin Infect Dis. 2015 Jul 1;61(1):40-8. doi: 10.1093/cid/civ217. Epub 2015 Mar 16.

2.

High levels of alcohol consumption increase the risk of advanced hepatic fibrosis in HIV/hepatitis C virus-coinfected patients: a sex-based analysis using transient elastography at enrollment in the HEPAVIH ANRS CO13 cohort.

Marcellin F, Roux P, Loko MA, Lions C, Caumont-Prim A, Dabis F, Salmon-Ceron D, Spire B, Carrieri MP; HEPAVIH (ANRS CO13) Study Group.

Clin Infect Dis. 2014 Oct 15;59(8):1190-2. doi: 10.1093/cid/ciu525. Epub 2014 Jul 11. No abstract available.

3.

Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.

Loko MA, Bani-Sadr F, Valantin MA, Lascoux-Combe C, Fontaine H, Bonnard P, Gervais A, Bouchaud O, Garipuy D, Quertainmont Y, Vittecoq D, Tehrani MS, Winnock M, Dabis F, Salmon D; ANRS CO 13 HEPAVIH Study Group.

Antivir Ther. 2012;17(7):1335-43. doi: 10.3851/IMP2419. Epub 2012 Oct 10.

PMID:
23052829
4.

Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France).

Salmon-Ceron D, Cohen J, Winnock M, Roux P, Sadr FB, Rosenthal E, Martin IP, Loko MA, Mora M, Sogni P, Spire B, Dabis F, Carrieri MP; HEPAVIH group.

BMC Health Serv Res. 2012 Mar 12;12:59. doi: 10.1186/1472-6963-12-59.

5.

Children who acquire HIV infection perinatally are at higher risk of early death than those acquiring infection through breastmilk: a meta-analysis.

Becquet R, Marston M, Dabis F, Moulton LH, Gray G, Coovadia HM, Essex M, Ekouevi DK, Jackson D, Coutsoudis A, Kilewo C, Leroy V, Wiktor SZ, Nduati R, Msellati P, Zaba B, Ghys PD, Newell ML; UNAIDS Child Survival Group.

PLoS One. 2012;7(2):e28510. doi: 10.1371/journal.pone.0028510. Epub 2012 Feb 23.

6.

Primary liver cancer is more aggressive in HIV-HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavih and CO12 Cirvir).

Bourcier V, Winnock M, Ait Ahmed M, Sogni P, Pambrun E, Poizot-Martin I, Chaffaut C, Chevret S, Trinchet JC, Salmon D; ANRS CO13 Hepavih study group; ANRS CO12 Cirvir study group.

Clin Res Hepatol Gastroenterol. 2012 Jun;36(3):214-21. doi: 10.1016/j.clinre.2011.11.002. Epub 2011 Dec 19.

PMID:
22189509
7.

The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010.

Loko MA, Salmon D, Carrieri P, Winnock M, Mora M, Merchadou L, Gillet S, Pambrun E, Delaune J, Valantin MA, Poizot-Martin I, Neau D, Bonnard P, Rosenthal E, Barange K, Morlat P, Lacombe K, Gervais A, Rouges F, See AB, Lascoux-Combe C, Vittecoq D, Goujard C, Duvivier C, Spire B, Izopet J, Sogni P, Serfaty L, Benhamou Y, Bani-Sadr F, Dabis F; ANRS CO 13 HEPAVIH Study Group.

BMC Infect Dis. 2010 Oct 22;10:303. doi: 10.1186/1471-2334-10-303.

8.

A prospective longitudinal study of the impact of early postnatal vs. chronic maternal depressive symptoms on child development.

Sutter-Dallay AL, Murray L, Dequae-Merchadou L, Glatigny-Dallay E, Bourgeois ML, Verdoux H.

Eur Psychiatry. 2011 Nov;26(8):484-9. doi: 10.1016/j.eurpsy.2010.05.004. Epub 2010 Jul 10.

PMID:
20621453
9.

18-month effectiveness of short-course antiretroviral regimens combined with alternatives to breastfeeding to prevent HIV mother-to-child transmission.

Leroy V, Ekouevi DK, Becquet R, Viho I, Dequae-Merchadou L, Tonwe-Gold B, Rouet F, Sakarovitch C, Horo A, Timité-Konan M, Rouzioux C, Dabis F; ANRS 1201/1202 DITRAME PLUS Study Group.

PLoS One. 2008 Feb 20;3(2):e1645. doi: 10.1371/journal.pone.0001645.

10.

Beneficial effects of offering prenatal HIV counselling and testing on developing a HIV preventive attitude among couples. Abidjan, 2002-2005.

Desgrées-Du-Loû A, Brou H, Djohan G, Becquet R, Ekouevi DK, Zanou B, Viho I, Allou G, Dabis F, Leroy V; ANRS 1201/1202/1253 Ditrame Plus Study Group.

AIDS Behav. 2009 Apr;13(2):348-55. Epub 2007 Nov 6.

PMID:
17985231
11.

Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission.

Dabis F, Bequet L, Ekouevi DK, Viho I, Rouet F, Horo A, Sakarovitch C, Becquet R, Fassinou P, Dequae-Merchadou L, Welffens-Ekra C, Rouzioux C, Leroy V; ANRS 1201/1202 DITRAME PLUS Study Group.

AIDS. 2005 Feb 18;19(3):309-18.

12.

Estimating the efficacy of interventions to prevent mother-to-child transmission of human immunodeficiency virus in breastfeeding populations: comparing statistical methods.

Alioum A, Cortina-Borja M, Dabis F, Dequae-Merchadou L, Haverkamp G, Hughes J, Karon J, Leroy V, Newell ML, Richardson BA, van Weert L, Weverling GJ; Ghent Group.

Am J Epidemiol. 2003 Sep 15;158(6):596-605.

13.

Estimating the efficacy of interventions to prevent mother-to-child transmission of HIV in breast-feeding populations: development of a consensus methodology.

Alioum A, Dabis F, Dequae-Merchadou L, Haverkamp G, Hudgens M, Hughes J, Karon J, Leroy V, Newell ML, Richardson B, Weverling GJ.

Stat Med. 2001 Dec 15;20(23):3539-56.

PMID:
11746336
14.

Incidence and risk factors of severe hypertriglyceridaemia in the era of highly active antiretroviral therapy: the Aquitaine Cohort, France, 1996-99.

Thiébaut R, Dequae-Merchadou L, Ekouevi DK, Mercié P, Malvy D, Neau D, Dabis F; Groupe d'Epidémiologie Clinique du SIDA en Aquitane (GECSA).

HIV Med. 2001 Apr;2(2):84-8.

15.

18-Month mortality and perinatal exposure to zidovudine in West Africa.

Dabis F, Elenga N, Meda N, Leroy V, Viho I, Manigart O, Dequae-Merchadou L, Msellati P, Sombie I; DITRAME Study Group.

AIDS. 2001 Apr 13;15(6):771-9.

PMID:
11371692
16.

Dual nucleoside regimens in nonadvanced HIV infection: prospective follow-up of 130 patients, Aquitaine Cohort, 1996 to 1998. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).

Morlat P, Marimoutou C, Dequae-Merchadou L, Pellegrin I, Mercié P, Neau D, Beylot J, Dabis F.

J Acquir Immune Defic Syndr. 2000 Mar 1;23(3):255-60.

PMID:
10839661
17.

Increase in CD3+ CD4- T lymphocytes in patients with AIDS and disseminated Mycobacterium avium-intracellulare complex infection: a prospective study. GECSA. Groupe d'Epidemiologie Clinique du SIDA en Aquitaine.

Bonnet F, Dequae-Merchadou L, Taupin JL, Sire S, Dupon M, Ragnaud JM, Lacoste D, Texier-Maugein J, Romagné F, Dabis F, Pellegrin JL, Moreau JF.

Microbes Infect. 1999 Aug;1(10):771-6.

PMID:
10816082
18.

A multi-center trial of the effects of oral nutritional supplementation in critically ill older inpatients. GAGE Group. Groupe Aquitain Geriatrique d'Evaluation.

Bourdel-Marchasson I, Barateau M, Rondeau V, Dequae-Merchadou L, Salles-Montaudon N, Emeriau JP, Manciet G, Dartigues JF.

Nutrition. 2000 Jan;16(1):1-5.

PMID:
10674226
19.

Predictive factors of occurrence of cytomegalovirus disease and impact on survival in the Aquitaine Cohort in France, 1985 to 1994. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.

Saillour F, Bernard N, Dequae-Merchadou L, Marimoutou C, Journot V, Dabis F.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Feb 1;17(2):171-8.

PMID:
9473020
20.

Splenectomy and prognosis of HIV infection. Group d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA)

Morlat P, Dequae-Merchadou L, Dabis F, Chene G, Salamon R, Beylot J.

AIDS. 1996 Sep;10(10):1170-2. No abstract available.

PMID:
8874637
Items per page

Supplemental Content

Loading ...
Write to the Help Desk